Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-expanded mesenchymal stromal cell cultures.

Das R, Roosloot R, van Pel M, Schepers K, Driessen M, Fibbe WE, de Bruijn JD, Roelofs H.

J Transl Med. 2019 Jul 24;17(1):241. doi: 10.1186/s12967-019-1989-x.

2.

De novo generation of a functional human thymus from induced pluripotent stem cells.

Chhatta AR, Cordes M, Hanegraaf MAJ, Vloemans S, Cupedo T, Cornelissen JJ, Carlotti F, Salvatori D, Pike-Overzet K, Fibbe WE, Hoeben RC, Mikkers HMM, Staal FJT.

J Allergy Clin Immunol. 2019 Jul 16. pii: S0091-6749(19)30938-8. doi: 10.1016/j.jaci.2019.05.042. [Epub ahead of print] No abstract available.

PMID:
31323248
3.

Hypercholesterolemia affects cardiac function, infarct size and inflammation in APOE*3-Leiden mice following myocardial ischemia-reperfusion injury.

Pluijmert NJ, den Haan MC, van Zuylen VL, Steendijk P, de Boer HC, van Zonneveld AJ, Fibbe WE, Schalij MJ, Quax PHA, Atsma DE.

PLoS One. 2019 Jun 14;14(6):e0217582. doi: 10.1371/journal.pone.0217582. eCollection 2019.

4.

Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas.

Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters KCMJ, van der Meulen-de Jong AE.

J Crohns Colitis. 2019 Jun 14. pii: jjz116. doi: 10.1093/ecco-jcc/jjz116. [Epub ahead of print]

PMID:
31197361
5.

Cytokine-induced hematopoietic stem and progenitor cell mobilization: unraveling interactions between stem cells and their niche.

de Kruijf EFM, Fibbe WE, van Pel M.

Ann N Y Acad Sci. 2019 Apr 21. doi: 10.1111/nyas.14059. [Epub ahead of print] Review.

PMID:
31006885
6.

FOXO3, a Molecular Search for the Fountain of Youth.

Fibbe WE, Shi Y.

Cell Stem Cell. 2019 Mar 7;24(3):351-352. doi: 10.1016/j.stem.2019.02.008.

PMID:
30849363
7.

Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia.

Mann I, Tseng CCS, Rodrigo SF, Koudstaal S, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Geus-Oei LF, Lamb HJ, Wolterbeek R, Zwaginga JJ, Fibbe WE, Westinga K, Bax JJ, Doevendans PA, Schalij MJ, Chamuleau SAJ, Atsma DE.

Neth Heart J. 2019 Feb;27(2):81-92. doi: 10.1007/s12471-018-1213-2.

8.

Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche.

Aleksinskaya MA, Monge M, Siebelt M, Slot EM, Koekkoek KM, de Bruin RG, Massy ZA, Weinans H, Rabelink TJ, Fibbe WE, Jan van Zonneveld A, van Pel M.

Sci Rep. 2018 Oct 18;8(1):15385. doi: 10.1038/s41598-018-33979-7.

9.

Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.

Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA.

Eur J Haematol. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]

PMID:
30084111
10.

No Clinical Benefit of Intramuscular Delivery of Bone Marrow-derived Mononuclear Cells in Nonreconstructable Peripheral Arterial Disease: Results of a Phase-III Randomized-controlled Trial.

Lindeman JHN, Zwaginga JJ, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ, Fibbe WE, Hamming JF.

Ann Surg. 2018 Nov;268(5):756-761. doi: 10.1097/SLA.0000000000002896.

PMID:
30004916
11.

Mesenchymal stromal cells induce a permissive state in the bone marrow that enhances G-CSF-induced hematopoietic stem cell mobilization in mice.

de Kruijf EFM, Zuijderduijn R, Stip MC, Fibbe WE, van Pel M.

Exp Hematol. 2018 Aug;64:59-70.e2. doi: 10.1016/j.exphem.2018.05.002.

PMID:
29775645
12.

Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long-term results.

Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

J Interv Cardiol. 2017 Oct;30(5):440-447. doi: 10.1111/joic.12408. Epub 2017 Jul 28.

PMID:
28752630
13.

Lupus nephritis: Mesenchymal stromal cells in lupus nephritis.

Fibbe WE, Rabelink TJ.

Nat Rev Nephrol. 2017 Jul 18;13(8):452-453. doi: 10.1038/nrneph.2017.100. No abstract available.

PMID:
28719600
14.

Clinical-Grade Isolated Human Kidney Perivascular Stromal Cells as an Organotypic Cell Source for Kidney Regenerative Medicine.

Leuning DG, Reinders ME, Li J, Peired AJ, Lievers E, de Boer HC, Fibbe WE, Romagnani P, van Kooten C, Little MH, Engelse MA, Rabelink TJ.

Stem Cells Transl Med. 2017 Feb;6(2):405-418. doi: 10.5966/sctm.2016-0053. Epub 2016 Sep 20.

15.

Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough?

den Haan MC, van Zuylen VL, Pluijmert NJ, Schutte CI, Fibbe WE, Schalij MJ, Roelofs H, Atsma DE.

PLoS One. 2016 Apr 6;11(4):e0152938. doi: 10.1371/journal.pone.0152938. eCollection 2016.

16.

A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.

Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MI, Taube C, Hiemstra PS.

QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.

17.

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L.

Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.

18.

The human and murine hematopoietic stem cell niches: are they comparable?

van Pel M, Fibbe WE, Schepers K.

Ann N Y Acad Sci. 2016 Apr;1370(1):55-64. doi: 10.1111/nyas.12994. Epub 2015 Dec 29. Review.

PMID:
26713726
19.

Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization.

Schepers K, Fibbe WE.

Ann N Y Acad Sci. 2016 Apr;1370(1):15-23. doi: 10.1111/nyas.12984. Epub 2015 Dec 29. Review.

PMID:
26713608
20.

Visualizing Human Hematopoietic Stem Cell Trafficking In Vivo Using a Zebrafish Xenograft Model.

Staal FJ, Spaink HP, Fibbe WE.

Stem Cells Dev. 2016 Feb 15;25(4):360-5. doi: 10.1089/scd.2015.0195. Epub 2016 Jan 19.

PMID:
26650921
21.

Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.

Reinders ME, Dreyer GJ, Bank JR, Roelofs H, Heidt S, Roelen DL, Zandvliet ML, Huurman VA, Fibbe WE, van Kooten C, Claas FH, Rabelink TJ, de Fijter JW.

J Transl Med. 2015 Nov 4;13:344. doi: 10.1186/s12967-015-0700-0.

22.

Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus.

Brugman MH, Wiekmeijer AS, van Eggermond M, Wolvers-Tettero I, Langerak AW, de Haas EF, Bystrykh LV, van Rood JJ, de Haan G, Fibbe WE, Staal FJ.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E6020-7. doi: 10.1073/pnas.1519118112. Epub 2015 Oct 19.

23.

Reduction of healthcare utilization after bone marrow cell therapy for refractory angina pectoris.

Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

Int J Cardiol. 2016 Jan 1;202:571-2. doi: 10.1016/j.ijcard.2015.09.103. Epub 2015 Sep 28. No abstract available.

PMID:
26447664
24.

Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells.

Wiekmeijer AS, Pike-Overzet K, IJspeert H, Brugman MH, Wolvers-Tettero IL, Lankester AC, Bredius RG, van Dongen JJ, Fibbe WE, Langerak AW, van der Burg M, Staal FJ.

J Allergy Clin Immunol. 2016 Feb;137(2):517-526.e3. doi: 10.1016/j.jaci.2015.08.022. Epub 2015 Oct 4.

PMID:
26441229
25.

Repeated Intramyocardial Bone Marrow Cell Injection in Previously Responding Patients With Refractory Angina Again Improves Myocardial Perfusion, Anginal Complaints, and Quality of Life.

Mann I, Rodrigo SF, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Roos A, Wolterbeek R, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

Circ Cardiovasc Interv. 2015 Aug;8(8). pii: e002740. doi: 10.1161/CIRCINTERVENTIONS.115.002740.

PMID:
26259770
26.

Myocardial infarction models in NOD/Scid mice for cell therapy research: permanent ischemia vs ischemia-reperfusion.

van Zuylen VL, den Haan MC, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE.

Springerplus. 2015 Jul 10;4:336. doi: 10.1186/s40064-015-1128-y. eCollection 2015.

27.

Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice.

Rosen C, Shezen E, Aronovich A, Klionsky YZ, Yaakov Y, Assayag M, Biton IE, Tal O, Shakhar G, Ben-Hur H, Shneider D, Vaknin Z, Sadan O, Evron S, Freud E, Shoseyov D, Wilschanski M, Berkman N, Fibbe WE, Hagin D, Hillel-Karniel C, Krentsis IM, Bachar-Lustig E, Reisner Y.

Nat Med. 2015 Aug;21(8):869-79. doi: 10.1038/nm.3889. Epub 2015 Jul 13.

PMID:
26168294
28.

Mesenchymal stromal cells and hematopoietic stem cell transplantation.

Bernardo ME, Fibbe WE.

Immunol Lett. 2015 Dec;168(2):215-21. doi: 10.1016/j.imlet.2015.06.013. Epub 2015 Jun 25. Review.

PMID:
26116911
29.

Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease.

Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga JJ, Verspaget HW, Fibbe WE, van der Meulen-de Jong AE, Hommes DW.

Gastroenterology. 2015 Oct;149(4):918-27.e6. doi: 10.1053/j.gastro.2015.06.014. Epub 2015 Jun 25.

PMID:
26116801
30.

Post-myocardial infarct inflammation and the potential role of cell therapy.

van Zuylen VL, den Haan MC, Geutskens SB, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE.

Cardiovasc Drugs Ther. 2015 Feb;29(1):59-73. doi: 10.1007/s10557-014-6568-z. Review.

PMID:
25583678
31.

Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.

Reinders ME, Bank JR, Dreyer GJ, Roelofs H, Heidt S, Roelen DL, Al Huurman V, Lindeman J, van Kooten C, Claas FH, Fibbe WE, Rabelink TJ, de Fijter JW.

J Transl Med. 2014 Dec 10;12:331. doi: 10.1186/s12967-014-0331-x.

32.

SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking.

Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, Kazmi M, Hawkey C, Simoes BP, Leblanc K, Fibbe WE, Moore J, Snarski E, Martin T, Hiepe F, Velardi A, Toubert A, Snowden JA, Farge D.

Bone Marrow Transplant. 2015 Feb;50(2):173-80. doi: 10.1038/bmt.2014.251. Epub 2014 Nov 10. Review.

33.

Control of immune responses by mesenchymal stromal cells.

Fibbe WE, Bernardo ME.

Rinsho Ketsueki. 2014 Oct;55(10):2190-4. Review. Japanese. No abstract available.

PMID:
25297786
34.

Successful RAG1-SCID gene therapy depends on the level of RAG1 expression.

Pike-Overzet K, Baum C, Bredius RG, Cavazzana M, Driessen GJ, Fibbe WE, Gaspar HB, Hoeben RC, Lagresle-Peyrou C, Lankester A, Meij P, Schambach A, Thrasher A, Van Dongen JJ, Zwaginga JJ, Staal FJ.

J Allergy Clin Immunol. 2014 Jul;134(1):242-3. doi: 10.1016/j.jaci.2014.04.033. Epub 2014 Jun 26. No abstract available.

PMID:
25117803
35.

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group.

JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368.

36.

Predictors of response to intramyocardial bone marrow cell treatment in patients with refractory angina and chronic myocardial ischemia.

Rodrigo SF, van Ramshorst J, Mann I, Leong DP, Cannegieter SC, Al Younis I, Dibbets-Schneider P, de Roos A, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE.

Int J Cardiol. 2014 Aug 20;175(3):539-44. doi: 10.1016/j.ijcard.2014.06.039. Epub 2014 Jul 2.

PMID:
25023791
37.

Sustained Engraftment of Cryopreserved Human Bone Marrow CD34(+) Cells in Young Adult NSG Mice.

Wiekmeijer AS, Pike-Overzet K, Brugman MH, Salvatori DC, Egeler RM, Bredius RG, Fibbe WE, Staal FJ.

Biores Open Access. 2014 Jun 1;3(3):110-6. doi: 10.1089/biores.2014.0008.

38.

Peripheral blood hematopoietic stem and progenitor cell frequency is unchanged in patients with alpha-1-antitrypsin deficiency.

de Kruijf EJ, Alkemade GM, van Os R, Fibbe WE, van Pel M.

Int J Hematol. 2014 Jun;99(6):714-20. doi: 10.1007/s12185-014-1581-3. Epub 2014 Apr 22.

PMID:
24752699
39.

Optimizing reporter constructs for in vivo bioluminescence imaging of interferon-γ stimulated mesenchymal stromal cells.

Perez-Galarza J, Carlotti F, Rabelink MJ, Cramer S, Hoeben RC, Fibbe WE, van Pel M.

Exp Hematol. 2014 Sep;42(9):793-803.e1. doi: 10.1016/j.exphem.2014.04.004. Epub 2014 Apr 15.

PMID:
24746876
40.

Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: a potential role for heterologous immunity.

Westerhuis G, de Witte M, Schumacher TN, Toes RE, Fibbe WE.

Exp Hematol. 2014 Sep;42(9):753-60. doi: 10.1016/j.exphem.2014.04.001. Epub 2014 Apr 13.

PMID:
24732702
41.

Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury: a pilot study.

Hogendoorn S, Duijnisveld BJ, van Duinen SG, Stoel BC, van Dijk JG, Fibbe WE, Nelissen RG.

Bone Joint Res. 2014 Feb 24;3(2):38-47. doi: 10.1302/2046-3758.32.2000229. Print 2014.

42.

Effect of intramyocardial bone marrow-derived mononuclear cell injection on cardiac sympathetic innervation in patients with chronic myocardial ischemia.

van Ramshorst J, Beeres SL, Rodrigo SF, Dibbets-Schneider P, Scholte AJ, Fibbe WE, Zwaginga JJ, Schalij MJ, Bax JJ, Atsma DE.

Int J Cardiovasc Imaging. 2014 Mar;30(3):583-9. doi: 10.1007/s10554-014-0377-0. Epub 2014 Jan 31.

PMID:
24481723
43.

Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?

Moll G, Hult A, von Bahr L, Alm JJ, Heldring N, Hamad OA, Stenbeck-Funke L, Larsson S, Teramura Y, Roelofs H, Nilsson B, Fibbe WE, Olsson ML, Le Blanc K.

PLoS One. 2014 Jan 13;9(1):e85040. doi: 10.1371/journal.pone.0085040. eCollection 2014.

44.

Mesenchymal stromal cells: sensors and switchers of inflammation.

Bernardo ME, Fibbe WE.

Cell Stem Cell. 2013 Oct 3;13(4):392-402. doi: 10.1016/j.stem.2013.09.006. Review.

45.

Multipotent stromal cells skew monocytes towards an anti-inflammatory function: the link with key immunoregulatory molecules.

Melief SM, Geutskens SB, Fibbe WE, Roelofs H.

Haematologica. 2013 Sep;98(9):e121-2. doi: 10.3324/haematol.2013.093864. No abstract available.

46.

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.

Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F.

Br J Haematol. 2013 Nov;163(4):501-9. doi: 10.1111/bjh.12545. Epub 2013 Aug 31.

PMID:
23992039
47.

Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up.

Rodrigo SF, van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, Roelofs H, Al Younis I, Dibbets-Schneider P, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE.

J Cardiovasc Transl Res. 2013 Oct;6(5):816-25. doi: 10.1007/s12265-013-9507-7. Epub 2013 Aug 28.

48.

MSCs: science and trials.

Fibbe WE, Dazzi F, LeBlanc K.

Nat Med. 2013 Jul;19(7):812-3. doi: 10.1038/nm.3222. No abstract available.

PMID:
23836217
49.

Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages.

Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, Roelofs H.

Stem Cells. 2013 Sep;31(9):1980-91. doi: 10.1002/stem.1432.

50.

Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts.

Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H.

Stem Cells Transl Med. 2013 Jun;2(6):455-63. doi: 10.5966/sctm.2012-0184. Epub 2013 May 21.

Supplemental Content

Loading ...
Support Center